The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA’s National Precision Oncology Program (NPOP).
 
Alice Nono Djotsa
No Relationships to Disclose
 
David Winski
No Relationships to Disclose
 
Theresa Hoang-Anh Nguyen
No Relationships to Disclose
 
Sara Ahmed
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; PierianDx
 
John H Strickler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Lilly; Natera (Inst); Pfizer; Pionyr; Roche/Genentech; Seagen; Silverback Therapeutics; Takeda; Viatris; Zentalis
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Travel, Accommodations, Expenses - Seagen
 
Daniel Jacob Becker
No Relationships to Disclose
 
Vishal Vashistha
Employment - UnitedHealthcare (I)
Research Funding - IBM (Inst)
Other Relationship - IBM
(OPTIONAL) Uncompensated Relationships - IBM
 
Michael J. Kelley
Research Funding - Bristol-Myers Squibb (Inst); EQRx; Genentech (Inst); Mirati Therapeutics; Novartis (Inst); Regeneron (Inst)